Identification of novel in vitro test systems for the determination of glucocorticoid receptor ligand-induced skin atrophy

Skin Pharmacology and Physiology

Volumn 23, Issue 3, 2010, Pages 139-151

  Schoepe, S ^a,b   Schacke H ^a   Bernd, A ^c   Zoller N ^c   Asadullah, K ^b,d  

^a Common Mechanism Research Berlin ^*  (Germany)

^b BAYER PHARMA AG   (Germany)

^c GOETHE UNIVERSITY   (Germany)

^d German Rheumatology Research Center   (Germany)

Author keywords

Glucocorticoid receptor ligand; In vitro test systems; Skin atrophy

Indexed keywords

BETAMETHASONE VALERATE; CELL MARKER; CLOBETASOL PROPIONATE; COLLAGEN TYPE 1; COLLAGEN TYPE 3; CYTOKINE; DEXAMETHASONE; GELATINASE A; GELATINASE B; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; HYDROCORTISONE; INTERSTITIAL COLLAGENASE; LIGAND; MOMETASONE FUROATE; PREDNICARBATE; SELECTIVE GLUCOCORTICOID RECEPTOR AGONIST; STROMELYSIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLOGICAL ACTIVITY; CELL ASSAY; CELL LINE; CELL STRAIN 3T3; COLLAGEN METABOLISM; COLLAGEN SYNTHESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE MARKER; DISEASE MODEL; ENZYME SYNTHESIS; EPIDERMIS; EVALUATION; FEMALE; HORMONAL REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; KERATINOCYTE; MOUSE; NONHUMAN; PILOT STUDY; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SKIN ATROPHY; SKIN BIOPSY; SKIN CELL;

3T3 CELLS; ADMINISTRATION, CUTANEOUS; ANIMALS; ANTI-INFLAMMATORY AGENTS; ATROPHY; CELL LINE; COLLAGEN; FEMALE; GLUCOCORTICOIDS; HUMANS; KERATINOCYTES; LIGANDS; MICE; MODELS, BIOLOGICAL; RATS; RATS, HAIRLESS; RATS, WISTAR; RECEPTORS, GLUCOCORTICOID; REPRODUCIBILITY OF RESULTS; SKIN;

EID: 73249151594     PISSN: 16605527     EISSN: None     Source Type: Journal    
DOI: 10.1159/000270386     Document Type: Article

References (30)

1. Sterry W, Asadullah K: Topical glucocorticoid therapy in dermatology. Ernst Schering Res Found Workshop 2002; 40: 39-54.
2. Niedner R: Glukokortikosteroide in der Dermatologie: Kontrollierter Einsatz erforderlich. Dtsch Arztebl 1996; 93:A2868-A2872.
3. Luger T, Loske KD, Elsner P, Kapp A, Kerscher M, Korting HC, Krutmann J, Nickner R, Rocken M, Ruzicka T, Schwarz T: Topische Dermatotherapie mit Glukokortikoiden - Therapeutischer Index. J Dtsch Dermatol Ges 2004; 2: 629-634.
4. Korting HC, Unholzer A, Schafer-Korting M, Tausch I, Gassmueller J, Nietsch KH: Different skin thinning potential of equipotent medium-strength glucocorticoids. Skin Pharmacol Appl Skin Physiol 2002; 15: 85-91.
5. Kimura T, Doi K: Dorsal skin reactions of hairless dogs to topical treatment with corticosteroids. Toxicol Pathol 1999; 27: 528-535.
6. Booth BA, Tan EM, Oikarinen A, Uitto J: Steroid-induced dermal atrophy: effects of glucocorticosteroids on collagen metabolism in human skin fibroblast cultures. Int J Dermatol 1982; 21: 333-337.
7. Mills CM, Marks R: Side effects of topical glucocorticoids. Curr Probl Dermatol 1993; 21: 122-131.
8. Kolbe L, Kligman AM, Schreiner V, Stoudemayer T: Corticosteroid-induced atrophy and barrier impairment measured by noninvasive methods in human skin. Skin Res Technol 2001; 7: 73-77.
9. Kao JS, Fluhr JW, Man MQ, Fowler AJ, Hachem JP, Crumrine D, Ahn SK, Brown BE, Elias PM, Feingold KR: Short-term glucocorticoid treatment compromises both permeability barrier homeostasis and stratum corneum integrity: inhibition of epidermal lipid synthesis accounts for functional abnormalities. J Invest Dermatol 2003; 120: 456-464.
10. Sheu HM, Yu HS, Sheen TC: Histochemical and ultrastructural studies on cutaneous side effects due to topical corticosteroids. 1. Changes in epidermis. Derm Sinica 1989; 7: 143-153.
11. Saarni H, Hopsu-Havu VK: The decrease of hyaluronate synthesis by anti-inflammatory steroids in vitro. Br J Dermatol 1978; 98: 445-449.
12. Lehmann P, Zheng P, Lavker RM, Kligman AM: Corticosteroid atrophy in human skin. A study by light, scanning, and transmission electron microscopy. J Invest Dermatol 1983; 81: 169-176.
13. Cutroneo KR, Rokowski R, Counts DF: Glucocorticoids and collagen synthesis: comparison of in vivo and cell culture studies. Coll Relat Res 1981; 1: 557-568.
14. Nuutinen P, Autio P, Hurskainen T, Oikarinen A: Glucocorticoid action on skin collagen: overview on clinical significance and consequences. J Eur Acad Dermatol Venereol 2001; 15: 361-362.
15. Schoepe S, Schacke H, May E, Asadullah K: Glucocorticoid therapy-induced skin atrophy. Exp Dermatol 2006; 15: 406-420.
16. Schacke H, Docke WD, Asadullah K: Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002; 96: 23-43.
17. Mirshahpanah P, Docke WD, Merbold U, Asadullah K, Rose L, Schacke H, Zollner TM: Superior nuclear receptor selectivity and therapeutic index of methylprednisolone aceponate versus mometasone furoate. Exp Dermatol 2007; 16: 753-761.
18. Schacke H, Schottelius A, Docke WD, Strehlke P, Jaroch S, Schmees N, Rehwinkel H, Hennekes H, Asadullah K: Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci USA 2004; 101: 227-232.
19. Wach F, Bosserhoff A, Kurzidym U, Nowok K, Landthaler M, Hein R: Effects of mometasone furoate on human keratinocytes and fibroblasts in vitro. Skin Pharmacol Appl Skin Physiol 1998; 11: 43-51.
20. Ponec M, De Haas C, Bachra BN, Polano MK: Effects of glucocorticosteroids on cultured human skin fibroblasts. 3. Transient inhibition of cell proliferation in the early growth stages and reduced susceptibility in later growth stages. Arch Dermatol Res 1979; 265: 219-227.
21. Schacke H, Berger M, Rehwinkel H, Asadullah K: Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index. Mol Cell Endocrinol 2007; 275: 109-117.
22. Kurzen H, Henrich C, Booken D, Poenitz N, Gratchev A, Klemke CD, Engstner M, Goerdt S, Maas-Szabowski N: Functional characterization of the epidermal cholinergic system in vitro. J Invest Dermatol 2006; 126: 2458-2472.
23. Mewes KR, Raus M, Bernd A, Zoller NN, Sattler A, Graf R: Elastin expression in a newly developed full-thickness skin equivalent. Skin Pharmacol Physiol 2007; 20: 85-95.
24. Schottelius AJ, Zugel U, Docke WD, Zollner TM, Rose L, Mengel A, Buchmann B, Becker A, Grutz G, Naundorf S, Friedrich A, Gaestel M, Asadullah K: The role of mitogen-activated protein kinase-activated protein kinase 2 in the p38/TNF-alpha pathway of systemic and cutaneous inflammation. J Invest Dermatol 2009, E-pub ahead of print.
25. Li YY, Bao M, Meurer J, Skuballa W, Bauman JG, Doecke WD, Zollner TM: The identification of a small molecule inhibitor that specifically reduces T cell-mediated adaptive but not LPS-mediated innate immunity by T cell membrane-monocyte contact bioassay. Immunol Lett 2008; 117: 114-118.
26. Zoller NN, Kippenberger S, Thaci D, Mewes K, Spiegel M, Sattler A, Schultz M, Bereiter- Hahn J, Kaufmann R, Bernd A: Evaluation of beneficial and adverse effects of glucocorticoids on a newly developed full-thickness skin model. Toxicol In Vitro 2008; 22: 747-759.
27. Zerbe GO: On Fieller's theorem and the general linear model. The Am Stat 1978; 32: 103-105.
28. Dixon WJ: Processing data for outliers. Biometrics 1953; 9: 74-89.
29. Wiedersberg S, Leopold CS, Guy RH: Bioavailability and bioequivalence of topical glucocorticoids. Eur J Pharm Biopharm 2008; 68: 453-466.
30. Commandeur S, de Gruijl FR, Willemze R, Tensen CP, El Ghalbzouri A: An in vitro three-dimensional model of primary human cutaneous squamous cell carcinoma. Exp Dermatol 2009; 18: 849-856.